M. Tulp

Functional versus chemical diversity: is biodiversity important for drug discovery?

Lars Bohlin, L. Bohlin, Martin Tulp, 2002, Trends in pharmacological sciences.

Unconventional natural sources for future drug discovery.

Lars Bohlin, L. Bohlin, Martin Tulp, 2004, Drug discovery today.

New 1-aryl-4-(biarylmethylene)piperazines as potential atypical antipsychotics sharing dopamine D(2)-receptor and serotonin 5-HT(1A)-receptor affinities.

C. Kruse, W. Kuipers, M. Tulp, 2001, Bioorganic & medicinal chemistry letters.

SAR study of 1-aryl-4-(phenylarylmethyl)piperazines as ligands for both dopamine D2 and serotonin 5-HT1A receptors showing varying degrees of (Ant)agonism. Selection of a potential atypical antipsychotic.

M. Tulp, Adri van den Hoogenband, Herman H van Stuivenberg, 2006, Chemical & pharmaceutical bulletin.

Rediscovery of known natural compounds: nuisance or goldmine?

Lars Bohlin, L. Bohlin, Martin Tulp, 2005, Trends in pharmacological sciences.

The effects of central myorelaxants on synaptically‐evoked primary afferent depolarization in the immature rat spinal cord in vitro

M. Tulp, R. Siarey, S. Long, 1994, British journal of pharmacology.

DU 127090: a highly potent, atypical dopamine receptor ligand — high potency but low efficacy at dopamine D2 receptors in vitro

C. Kruse, E. Ronken, M. Tulp, 2000, European Neuropsychopharmacology.

Ethopharmacological studies differentiate the effects of various serotonergic compounds on aggression in rats

B. Olivier, M. Tulp, J. Mos, 1990 .

Serotonin reuptake blockers: Is there preclinical evidence for their efficacy in obsessive–compulsive disorder?

J. Schipper, B. Olivier, M. Tulp, 1991 .